Accelerate licensing and collaboration deals across TAC and Molecular Glue discovery platforms and pipelines to validate capabilities, improve tissue specificity of protein homeostasis, and leverage known, undruggable targets across diseases.

URLs:
Brochure: https://go.evvnt.com/2864375-0?pid=91
Tickets: https://go.evvnt.com/2864375-2?pid=91

Prices:
Biotech, Pharma and Investors - On the Door: USD 3099.00,
Academics - On the Door: USD 2699.00,
Service Providers - On the Door: USD 5499.00

Speakers: Adam Gilbert, Executive Director, External Innovation Accelerator, Pfizer, Akihiro Furukawa, Director, Research and Technology Search and Evaluation, Daiichi Sankyo, Alexandra Joseph, Chief Scientific Officer, Photys Therapeutics, Andrew Combs, Chief Chemistry Officer, Prelude Therapeutics, Ann Rowley, Director Targeted Protein Degradation, Merck, Anna Rivkin, Chief Business Officer, Foghorn Therapeutics, Arnout Schepers, Chief Executive Officer, TenAces Biosciences, Brad Heckmann, Chief Scientific Officer, ASHA Therapeutics, Bret Williams, Senior Vice President of Research, Magnet Biomedicine, Carla Bauer, Director, Oncology Search and Evaluation, Business Development, Merck, Christopher Guenard, Vice President Corporate Development, Photys Therapeutics, Danette Daniels, Vice President, Protein Degrader Platform, Foghorn Therapeutics, Elena Diez, Senior Director External Innovation, Janssen, Giovanni Spagnolli, Co-founder and Chief Technology Officer, Sibylla Biotech, Gwenn Hansen, Chief Scientific Officer, Nurix Therapeutics, Miki Hayano, Business Development, Monte Rosa Therapeutics, Randolph Lopez, Chief Technology Officer and Co-Founder, A-Alpha Bio, Reza Mazhari, Chief Business Officer, TRIANA Biomedicines, Seth Goldblum, Senior Vice President - Corporate Development, Cullgen, Shu-Jen Chen, Chief Scientific Officer, AnHorn Medicines, Xiaodong Zhang, Business Development Search and Evaluation, Oncology and Haematology, Novartis, Yue Xiong, Chief Scientific Officer, Cullgen